As of April 17, 2026, Rhythm Pharmaceuticals's top three insider holders are David P Meeker (President And Ceo, 239.02K shares), Hunter C Smith (Chief Financial Officer, 116.61K shares), Yann Mazabraud (Evp, Head Of International, 66.03K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| David P Meeker | President And Ceo | 239,016 | 0 | 03 Feb, 2026 |
| Hunter C Smith | Chief Financial Officer | 116,611 | 0 | 02 Mar, 2026 |
| Yann Mazabraud | Evp, Head Of International | 66,030 | 0 | 03 Apr, 2026 |
| Pamela J. Cramer | Chief Human Resources Officer | 29,376 | 0 | 03 Feb, 2026 |
| Jennifer Kayden Lee | Evp, Head Of North America | 19,233 | 0 | 03 Feb, 2026 |
| Joseph Shulman | Chief Technical Officer | 18,970 | 0 | 03 Feb, 2026 |
| Edward T Mathers | - | 0 | 14,168 | 16 Mar, 2026 |
| William T. Roberts | Chief Accounting Officer | 7,872 | 0 | 31 Mar, 2023 |
| Alastair Garfield | Chief Scientific Officer | 7,763 | 0 | 03 Feb, 2026 |
| Edward T Mathers | - | 7,000 | 0 | 23 Jun, 2025 |
| Lynn A. Tetrault | - | 7,000 | 0 | 23 Jun, 2025 |
| Christophe Jean | - | 7,000 | 0 | 23 Jun, 2025 |
| David W J Mcgirr | - | 7,000 | 0 | 23 Jun, 2025 |
| Jennifer L Good | - | 7,000 | 0 | 23 Jun, 2025 |
| Stuart A Arbuckle | - | 7,000 | 0 | 23 Jun, 2025 |
| Camille L Bedrosian | - | 7,000 | 0 | 23 Jun, 2025 |
| Christopher Paul German | Corporate Controller Cao | 160 | 0 | 06 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 01 Apr, 2026 | Kimberly J Popovits | Restricted Stock Units | A | 6,808 | $0.00 | 6,808 | D | A |
| 01 Apr, 2026 | Yann Mazabraud | Common Stock | A | 12,875 | - | 66,030 | D | M |
| 01 Apr, 2026 | Kimberly J Popovits | Stock Options (Right to Buy) | A | 10,257 | $0.00 | 10,257 | D | A |
| 01 Apr, 2026 | Yann Mazabraud | Restricted Stock Units | D | 10,375 | $0.00 | 10,375 | D | M |
| 01 Apr, 2026 | Yann Mazabraud | Restricted Stock Units | D | 2,500 | $0.00 | 5,000 | D | M |
| 12 Mar, 2026 | Edward T Mathers | Common Stock | A | 4,199 | $0.00 | 14,168 | I | J |
| 04 Mar, 2026 | Christopher Paul German | Common Stock | A | 1,500 | $17.97 | 5,753 | D | M |
| 04 Mar, 2026 | Christopher Paul German | Common Stock | D | 5,614 | $89.56 | 160 | D | S |
| 04 Mar, 2026 | Christopher Paul German | Stock Options (Right to Buy) | D | 1,500 | $0.00 | 3,731 | D | M |
| 02 Mar, 2026 | Yann Mazabraud | Stock Options (Right to Buy) | A | 35,000 | $0.00 | 35,000 | D | A |
| 02 Mar, 2026 | Edward T Mathers | Common Stock | A | 4,198 | $0.00 | 9,969 | I | J |
| 01 Mar, 2026 | Christopher Paul German | Common Stock | A | 1,162 | - | 4,595 | D | M |
| 01 Mar, 2026 | Christopher Paul German | Common Stock | D | 342 | $94.94 | 4,253 | D | F |
| 01 Mar, 2026 | Christopher Paul German | Restricted Stock Units | D | 1,162 | $0.00 | 1,162 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Common Stock | A | 6,099 | $6.80 | 116,611 | D | M |
| 02 Mar, 2026 | Hunter C Smith | Stock Options (Right to Buy) | D | 6,099 | $0.00 | 91,401 | D | M |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 1,200 | $99.42 | 117,266 | D | S |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 200 | $100.52 | 117,066 | D | S |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 900 | $101.70 | 116,166 | D | S |
| 17 Feb, 2026 | Hunter C Smith | Common Stock | D | 1,069 | $103.00 | 115,097 | D | S |